For in vitro diagnostic use. Others Elecsys CA 15-3 II IVD Elecsys® CA 15-3 II CPS_000448 09755594190 CA 15-3 G2 Elecsys E2G 100 V1 CA 15-3 G2 Elecsys E2G 100 V1 07613336218334 Reagents, kits 100 tests cobas e 402/801 true 07027001214 CA 15-3 G2 Elecsys E2G 300 Elecsys CA 15-3 II 07613336194126 Reagents, kits 300 tests cobas e 402/801 true 03045838122 CA 15-3 G2 Elecsys cobas e 100 Elecsys CA 15-3 II 04015630918218 Reagents, kits 100 tests cobas e 411/601/602 true 07027001188 CA 15-3 G2 Elecsys E2G 300 Elecsys CA 15-3 II 07613336194133 Reagents, kits 300 tests cobas e 402/801 true 07027001190 CA 15-3 G2 Elecsys E2G 300 Elecsys CA 15-3 II 04015630939961 Reagents, kits 300 tests cobas e 402/801 true 03045838160 CA 15-3 G2 Elecsys cobas e 100 Elecsys CA 15-3 II 04015630934379 Reagents, kits 100 tests cobas e 411/601/602 true 03045838214 CA 15-3 G2 Elecsys cobas e 100 Elecsys CA 15-3 II 07613336161159 Reagents, kits 100 tests cobas e 411/601/602 true 03045838188 CA 15-3 G2 Elecsys cobas e 100 Elecsys CA 15-3 II 07613336161142 Reagents, kits 100 tests cobas e 411/601/602 09755594501 Elecsys CA 15-3 II en 1 FF0000000710AA0E FF0000000710AA0E 09755594190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum, Li‑heparin and EDTA plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09755594500 Elecsys CA 15-3 II en 1 FF000000066E350E FF000000066E340E 09755594190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patientsThe electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027001500 Elecsys CA 15-3 II en 8 FF0000000568140E FF0000000568140E 07027001190 07027001214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patientsThe electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 03045838500 Elecsys CA 15-3 II en 23 FF0000000448DE0E FF0000000005540E 03045838122 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patientsThe electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 03045838500 Elecsys CA 15-3 II en 24 FF0000000567D00E FF0000000567D00E 03045838122 03045838214 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patientsThe electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 07027001500 Elecsys CA 15-3 II en 7 FF000000049F840E FF000000044B3D0E 07027001190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patientsThe electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027001501 Elecsys CA 15-3 II en 4 FF0000000566510E FF0000000262F80E 07027001190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum, Li‑heparin and EDTA plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 03045838501 Elecsys CA 15-3 II en 7 FF00000006F8D20E FF0000000003550E 03045838160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunological in vitro assay for quantitative determination of CA 15‑3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aidin the early detection of recurrence in previously treated stage II and III breast cancer patientsfor monitoring response to therapy in metastatic breast cancer patients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en